What is the significance of China's accession to the Paris Convention for the pharmaceutical industry?

The Paris Convention stipulates that member countries have the right to make restrictive provisions on the technical field of patent protection according to their actual conditions. Considering that many countries in the world do not protect medicines, foods and chemicals, China does not recognize pharmaceutical patents. In the Drug Administration Law implemented in July 1985, it is clear that new drugs refer to drugs that have not been produced in China, so pharmaceutical companies in China are free to copy foreign patented drugs and produce and sell foreign patented drugs in China. In order to help pharmaceutical manufacturers in China master foreign advanced technology as soon as possible and promote the research and development of drugs in China, the Ministry of Health has formulated the Regulations on the Protection of New Drugs and Technology Transfer, which classifies new drugs into one, two, three and four categories, with protection periods of 8, 6, 4 and 3 years respectively, marking the establishment of the administrative protection system for new drugs in China. 65438-0998 After the establishment of National Medical Products Administration, the system was further developed.